Wave Life Sciences is a clinical-stage biotechnology company that develops RNA medicines to treat rare and common diseases using its proprietary PRISM platform, which combines multiple therapeutic modalities including RNA interference, RNA editing, and antisense silencing. The company's core innovation is stereopure oligonucleotide chemistry with precisely controlled stereochemistry, which enables enhanced potency and tissue delivery without requiring complex vehicles like lipid nanoparticles or viruses. Wave's lead programs target obesity, alpha-1 antitrypsin deficiency, metabolic liver disease, Duchenne muscular dystrophy, and Huntington's disease, with development supported by a major partnership with GSK that provides upfront funding and milestone payments, while Wave retains rights to its own programs and earns royalties on net sales.